Jefferies has initiated coverage on unlisted med-tech firm Molbio Diagnostics, projecting strong growth driven by its Truenat platform and digital pathology tools. The brokerage anticipates significant profit margin expansion by 2029, although investors in the unlisted space should note that the company is not currently listed on major Indian stock exchanges.
Jefferies has initiated coverage on Molbio Diagnostics, positioning the company as a key player in the Indian medical technology sector. The brokerage report outlines a positive outlook for the firm, driven by its expansion in both domestic and international markets. The analysis emphasizes the potential for the company's flagship Truenat molecular diagnostics platform and its portable platform and its portable X-ray portfolio to act as significant growth drivers over the next few years.
Financial projections from the brokerage suggest a robust growth trajectory, with anticipated compound annual growth rates of 22% for revenue and 47% for profit after tax between fiscal years 2026 and 2029. Central to this financial outlook is an expected 830-basis-point expansion in profit margins. Analysts attribute this potential efficiency gain to increased utilization of test-kit capacity, which is projected to rise from 58% in FY26 to 77% by FY29. Additionally, the company is pivoting toward higher-value products, with the scaling of its Optrascan digital pathology segment expected to contribute 11% of total sales by the end of the forecast period.
The business model at Molbio Diagnostics is transitioning from a focus on single-product molecular diagnostics to a broader health-tech and digital pathology portfolio. The company holds a significant number of patents, both in India and internationally, which the brokerage views as a protective layer for its ongoing research and development investments. This move toward product diversification is designed to reduce the company's reliance on any single technology, a shift that the brokerage believes strengthens the long-term business case.
For investors assessing this update, it is important to understand the context of the company's current structure. Molbio Diagnostics is a private entity and is not listed on the National Stock Exchange or the Bombay Stock Exchange. While shares may trade on private platforms for unlisted stocks, these investments carry inherent risks, including lower liquidity, limited public information, and less regulatory oversight compared to listed companies. The valuation and upside targets suggested by the brokerage are based on the firm's private market potential rather than the liquid, high-volume environment of public equity markets.
Looking ahead, the primary monitorables for stakeholders will be the actual execution of these growth plans, particularly the ability to scale the Optrascan segment and maintain the forecasted efficiency gains. The company's success in navigating global markets while competing with established diagnostic players will remain a critical factor in validating these long-term performance projections.